US Supreme Court refuses to hear Eli Lilly's (LLY)/Takeda appeal for Actos fraud lawsuit

The US Supreme Court's refusal to hear Eli Lilly and Takeda's appeal concerning the Actos fraud lawsuit suggests a likely unfavorable outcome for both companies, potentially leading to increased financial liabilities.

Newsquawk StaffPublished On the live feed at 3 more headlines followed before this page went public
Newsquawk headlinesUTC

US EQUITY OPEN: Stocks rally and oil tumbles as Trump halts attacks on key Iran infrastructure following talks

US President Trump, on Iran, says "we have had strong talks", and see where talks will lead to; have had major points of agreement, if they carry through, it will end the conflict

US Supreme Court refuses to hear Eli Lilly's (LLY)/Takeda appeal for Actos fraud lawsuit

Israeli Press, citing an Israeli official, says Israel is likely to stop any attacks on power stations and energy infrastructure in Iran, via Sky News Arabia

German Chancellor Merz spoke with US President Trump on Sunday evening; outlined concern over Iran situation, and shared worries over attacks on Iranian power plants

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This decision could impact investor sentiment in the pharmaceuticals sector, particularly concerning litigation risks, and may create ripple effects in stock valuations and sector performance moving forward.

Related headlines

The whole workspace, free to try.

Try it free